1541 — ImmuneOnco Biopharmaceuticals Shanghai Income Statement
0.000.00%
Last trade - 00:00- HK$3.31bn
- HK$3.38bn
- CNY0.39m
Annual income statement for ImmuneOnco Biopharmaceuticals Shanghai, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | — |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 5.07 | 0.538 | 0.386 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 737 | 403 | 378 |
| Operating Profit | -732 | -402 | -378 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -733 | -403 | -379 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -733 | -403 | -379 |
| Net Income Before Extraordinary Items | |||
| Net Income | -733 | -403 | -379 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -733 | -403 | -379 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -8.46 | -1.16 | -0.977 |